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Swissa, Moshe, Toshihiko Ohara, Moon-Hyoung Lee,
Sanjay Kaul, Prediman K. Shah, Hideki Hayashi, Peng-
Sheng Chen, and Hrayr S. Karagueuzian. Sildenafil-
nitric oxide donor combination promotes ventricular tachy-
arrhythmias in the swine right ventricle. Am J Physiol Heart
Circ Physiol 282: H1787–H1792, 2002. First published Jan-
uary 17, 2002; 10.1152/ajpheart.00607.2001.—We tested the
hypothesis that sildenafil, singly or in combination with
nitric oxide (NO) donors, promotes ventricular tachycardia
(VT) and ventricular fibrillation (VF). Vulnerability to VT/VF
was tested by rapid pacing in eight isolated normal swine
right ventricles (RV). The endocardial activation was opti-
cally mapped, and the dynamic action potential duration
(APD) restitution curves were constructed with metal micro-
electrodes. At baseline, no VT/VF could be induced. Sildenafil
(0.2 g/ml) or NO donor singly or in combination did not alter
VT/VF vulnerability. However, when 2 g/ml sildenafil was
combined with NO donors, the incidence of VT and VF rose
significantly (P  0.01). VT with a single periodic wavefront
was induced in five of eight RVs, and VF with multiple
wavefronts was induced in all eight RVs. The sildenafil-NO
donor pro-VT/VF combination significantly increased the
maximum slope of the APD restitution curve and the ampli-
tude of the APD alternans. The pro-VT/VF effects of silde-
nafil were reversible after drug-free Tyrode solution perfu-
sion. We conclude that a sildenafil (2 g/ml) and NO donor
combination increases VT/VF vulnerability in the normal RV
by a mechanism compatible with the restitution hypothesis.
ventricular fibrillation; electrical stimulation
SILDENAFIL (Viagra) is a popular drug that is used to
manage erectile dysfunction (9). Shah (18) first re-
ported two patients with extensive prior myocardial
infarction in whom ventricular tachycardia (VT) was
temporally associated with sildenafil use. From April
1998 through May 1999, a total of 1,473 major adverse
events associated with siledenafil use were reported to
the US Food and Drug Administration Internet site.
These adverse events included 522 deaths, 517 myo-
cardial infarctions, 255 sudden deaths or arrhythmias,
119 cardiovascular accidents, and 271 cases of syncope
or hypotension (2, 5a). The cause of death was myocar-
dial infarction in 200 patients, sudden death or ar-
rhythmia in 94 patients, and unknown in 187 patients.
Some of the patients who died suddenly, presumably
by VT/ventricular fibrillation (VF), were on concomi-
tant nitrate therapy. The American College of Cardi-
ology/American Heart Association consensus sug-
gested that neither sildenafil nor nitrates should be
used within 24 h of the other in any dose and by any
route of administration (5) because of doubling (syner-
gism) of maximal blood pressure reduction (24). At
present, however, there are no studies that have eval-
uated the direct proarrhythmic potential of silednafil
and its interaction with nitrates [i.e., nitric oxide (NO)
donors] independent of hemodynamic compromise. In
this study, we tested the hypothesis that sildenafil,
individually or in combination with NO donors, in-
creases ventricular vulnerability to VT/VF in the iso-
lated normal swine right ventricle (RV) during heart
rate acceleration and constant coronary perfusion.
MATERIALS AND METHODS
Tissue Preparation
All experiments were done in accordance with the National
Institutes of Health Guide for the Care and Use of Laboratory
Animals. Eight farm pigs (25–35 kg body wt) of either sex
were anesthetized with 20 mg/kg iv thiopental sodium. The
RV was isolated and perfused through the right coronary
artery at a constant flow rate of 30 ml/min with oxygenated
Tyrode solution as previously described (11).
Drug Perfusion
Sildenafil citrate (Pfizer) in tablet form (50 mg) was dis-
solved in 200 ml of Tyrode solution just before the experiment
to form a stock solution of 250 g/ml. The stock solution was
then filtered, and a clear solution was obtained. Two different
concentrations of sildenafil, 0.2 and 2 g/ml, were used.
These concentrations of sildenafil encompass plasma silde-
nafil levels reported in humans (0.13–1.5 g/ml) after oral
ingestion of 25- to 200-mg Viagra tablets (3, 10). We used 50
M sodium nitroprusside (n  7) or 10 M nitroglycerine
(n  4) as NO donors (1, 17). Nitroglycerine was used in four
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isolated RVs after washout of the nitroprusside to determine
if the NO donor species influences the proarrhythmic poten-
tial of sildenafil in the same RV.
Pacing and Optical Mapping
The isolated RV was paced with a bipolar electrode with
twice diastolic threshold current and 5-ms pulse width. The
nature of the global RV rhythm (VT or VF) was determined
by recording a pseudoelectrocardiogram (ECG) via two elec-
trodes placed on both sides of the RV (11). Endocardial
“action potentials” were recorded with a pure iridium metal
electrode as we have previously described (15). Testing of
VT/VF vulnerability and construction of dynamic action po-
tential duration (APD) restitution curves were made by pro-
gressively shorter pacing cycle lengths (CL) from 400 to loss
of 1:1 capture using twice diastolic current threshold and
5-ms pulse duration (4, 12). Pacing began at 400-ms CL and
then progressively decreased during the same pacing train
without pauses between the different pacing CLs. When 1:1
capture was lost, the pacing train was considered complete.
No further aggressive pacing protocols (i.e., higher current
strengths, burst pacing) (11) were used in this study. A pair
of defibrillating coil electrodes (CPI) was placed in the tissue
bath 1 cm away from either side of the isolated RV and was
connected to an HVS-02 external defibrillator (Ventritex;
Sunnyvale, CA). The optical mapping used in the present
study has been previously described in detail (13, 21). Briefly,
the isolated RVs were stained for 20 min with the voltage-
sensitive dye di-4-ANEPPS (Molecular Probes; Eugene, OR)
and excited using a solid state laser at a wavelength of 532
nm. Fluorescent and scattered light was collected using an
image-intensified charge-coupled device camera (Dalsa; On-
tario, Canada). The data were acquired simultaneously from
128  128 sites over a 3  3-cm area with a temporal
resolution of 2.3 ms. About 1.5- to 2-cm-wide edges of tissue
remained outside the mapped region. The fluorescent signals
were baseline subtracted and inverted. A moving median
filter was applied, after which the signals were normalized to
the average of the maximal five data points so that the range
of the maximum signal amplitude was the same for each
pixel. The signals of each pixel were then spatially averaged
with the signals of eight neighboring pixels to reduce noise.
Each pixel was then assigned a shade of red, representing the
fully depolarized state, yellow, representing the repolarizing
state, and black, representing the fully repolarized state. The
boundaries of the depolarizing regions were delineated by
red, and the repolarizing regions were delineated by green
lines.
Study Protocol
After baseline testing of VT/VF inducibility and construc-
tion of dynamic APD restitution curves, we tested the effects
of drug or drug combinations. In one protocol, the two NO
donors were perfused singly; in a second protocol, the higher
concentration of sildenafil (2 g/ml) was perfused alone. In
the remaining two protocols, the two NO donors were com-
bined with the lower (0.2 g/ml) and higher (2 g/ml) con-
centrations of sildenafil. The order of drug perfusion was
randomized, and a washout period of 20 min was allowed
between the two different drug perfusion protocols. After
each drug perfusion, the sequence of rapid pacing was re-
peated. The endocardial RV effective refractory period (ERP)
was determined by the extrastimulus method using twice
diastolic current threshold and 5-ms duration during regular
pacing at a CL of 300 ms.
Data Analysis
APD restitution curve slopes were determined using expo-
nential fits to the data. Student’s t-test, 2-test, or ANOVA
with Dunn’s (Bonferroni) correction was used for multiple
comparisons (6, 22). Values of P  0.05 were considered
significant. All data are presented as means  SD.
RESULTS
Vulnerability to VF
Table 1 shows the incidence of VT/VF in all eight
isolated RVs. At baseline, VF could be induced twice in
only one of eight isolated RVs (Table 1). In this RV, VF
could also be induced when it was perfused with a low
concentration of sildenafil and NO donor (Table 1). In
the remaining seven RVs, repeated trials (at least 5
trials in each RV for a total 44 trials) failed to induce
VF at baseline. Similarly, when the lower (0.2 g/ml)
or higher (2 g/ml) sildenafil concentration was per-
fused individually, no VF could be induced. Similarly,
no VF could be induced when the two NO donors were
perfused individually (Table 1). Because the effects of
the two NO donors were similar, the results were
pooled. When, however, 2 g/ml sildenafil was com-
bined with either of the two NO donors, VF was in-
duced in all eight RVs (P  0.01 for all comparisons;
Table 1). Induction of VF was reasonably reproducible
in all eight RVs (39 induced VF episodes of 75 trials,
Table 1. Effects of sildenafil and NOD, individually and in combination,
on the incidence of VT/VF during rapid pacing
Control NOD LCS  NOD HCS HCS  NOD Washout
Number of pig RVs 8 7 8 7 8 7
VT induction 0/8 1/7 1/8 0/7 5/8* 0/7
VF induction 1/8 0/7 1/8 0/7 8/8* 1/7
Number of trials 44 40 40 36 97 35
Number of VT episodes 0/42 1/40 1/39 0/36 22/58* 0/33
% VT episodes 0 2.5 2.5 0 38 0
Number of VF episodes 2/44 0/39 1/39 0/36 39/75* 2/35
% VF episodes 5 0 2.5 0 52 6
Number of VT/VF episodes 2/44 1/40 2/40 0/36 61/97* 2/35
% VT/VF episodes 6 2.5 5 0 63 6
Values are means  SE. VT, ventricular tachycardia; VF, ventricular fibrillation; NOD, nitric oxide donors [sodium nitroprusside (50 M)
or nitroglycerine (10 M)]; LCS and HCS, low (0.2 g/ml) and high (2 g/ml) concentrations of sildenafil, respectively; RV, right ventricle.
*P  0.01 for all comparisons.
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52%; Table 1). The mean VF CL was 99.34  10 ms
(range 80–113 ms). In 17 episodes, the onset of VF was
preceded by three to five beats of periodic activations
(VT), and, in 16 episodes, rapid pacing degenerated to
VF immediately without a prior transient period of VT.
The pro-VF of the 2 g/ml sildenafil-NO donor combi-
nation was reversible upon 20 min of a drug-free wash-
out period (Table 1).
Vulnerability to VT
At baseline, VT could not be induced in any of the
eight isolated RVs. NO donor singly or combined with
the low concentration of sildenafil could induce VT in
only one of eight isolated RVs (Table 1). The high
concentration of sildenafil also failed to induce VT
(Table 1). However, when the higher concentration of
sildenafil was combined with NO donor, VT was in-
duced in five of eight RVs (22 induced VT episodes of 58
trials, 38%, P  0.01 for all comparisons; Table 1). VT
had a mean CL of 169 30 ms (range 110–230 ms) and
monomorphic ECG characteristics. The VT could last
for 10 min, often requiring cardioversion for termi-
nation. The period of the VT was either slower (n  12)
or faster (n  5) than the pacing CL that induced the
VT. The mean pacing CL that induced VT was 182 
39 ms (range 110–250 ms). Three episodes of VT with
a mean CL of 157  12 ms were initiated during
regular pacing at a CL of 400 ms within 5 min of high
sildenafil concentration-NO donor perfusion. The
pro-VT effects of the 2 g/ml sildenafil-NO donor com-
bination were reversible within 20 min of drug-free
perfusion in all five RVs (Table 1).
Activation Pattern During VT/VF
The mapped VF episodes (n 22) were characterized
by the presence of three to four independent wave-
fronts propagating in different directions, consistent
with our previous reports (26). In contrast, however,
mapped VT episodes (n  15) showed regular activa-
tion patterns (n  13) that were initiated either from
the border, outside the mapped region (n  12), or the
center (n  1) of the mapped tissue. Figure 1A illus-
trates an episode of VT initiated from the center of the
tissue by a periodic discharge mechanism. In one epi-
sode, the VT was sustained by a single counterclock-
wise-rotating spiral with a period of 130 ms (Fig. 1B).
APD Restitution and Refractoriness
NO donors singly and in combination with either the
low or high sildenafil concentration significantly (P 
Fig. 1. Optical snapshots during ventricular tachycardia (VT) induced during perfusion of a 2,000 ng/ml sildenafil
and 50 M sodium nitroprusside combination in an isolated perfused swine right ventricle. The most depolarized
region is red and the most repolarized is black. The red and green lines depict wavefront and waveback,
respectively. The number under each frame is the time (in ms), starting from zero (chosen arbitrarily). A: note the
presence of a focal activation that gives rise to a large concentric activation. B: episode of induced VT sustained by
a large counterclockwise (arrow) reentrant wavefront. Stim, stimulus artifact; CL, cycle length; ECG, pseudoelec-
trocardiogram; AP, action potential; BECG, bipolar electrogram.
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0.05) increased the maximum slope of the APD resti-
tution curve compared with the control (Table 2). The
high concentration of sildenafil alone had no significant
effect on the maximum slope of the APD restitution
(Table 2). The high concentration sildenafil-NO donor
combination changed the APD compared with the con-
trol (baseline), which was CL dependent. While at
400-ms CL, the drug combination shortened the APD
compared with the control; at a 240-ms pacing CL (i.e.,
the shortest CL with regular 1:1 capture), the APD
prolonged significantly compared with the control (Ta-
ble 2). The combination of the higher concentration of
sildenafil and NO donor was the only drug regimen
that simultaneously caused a significant increase in
the maximum slope of the APD restitution curve (1.3
0.1 vs. 1.9  0.5, P  0.05) and the APD (171  8 vs.
179  10 ms, P  0.05; Table 2) compared with the
control. No other drug or drug combination compared
with the control had these simultaneous effects on the
APD restitution and on the APD at the shortest cap-
tured pacing CL. Consistent with the restitution hy-
pothesis, these two effects (increases in the slope of the
APD restitution and APD) (7, 25) promote APD oscil-
lations with increasing amplitude during rapid pacing.
Figure 2 illustrates an example of increasing ampli-
tude of the APD gradient with the high concentration
of sildenafil and NO donor that precedes VF.
DISCUSSION
The ability of the sildenafil-NO donor combination to
promote VT/VF in the isolated perfused normal swine
RV constitutes the major finding of this study. An
equally important finding was the lack of proarrhyth-
mic effect when the same concentration of sildenafil
was perfused singly or at lower concentration with or
without a NO donor.
Mechanisms of VT/VF Induced by Sildenafil-NO
Donor Combination
Automatic mechanisms. NO stimulates the forma-
tion of cGMP, and sildenafil inhibits its degradation by
inhibiting phosphodiesterase type 5 (PDE5) activity,
causing a net increase in intracellular cGMP concen-
trations (3, 20). Although a selective inhibitor of PDE5,
sildenafil was shown to also inhibit PDE1, an impor-
tant cardiac PDE (23). Recent work has shown that
sildenafil may significantly increase both cGMP and
cAMP levels in isolated human cardiac tissue through
the inhibition of PDE1 (19). An increase in cellular
cGMP has been shown to stimulate the pacemaker
current, which may promote an “automatic” tachycar-
dia (14). Whereas an automatic mechanism might
cause a focal activity, an intramural reentry (scroll
wave) that periodically activates an endocardial site
Table 2. Effects of sildenafil and NOD, individually and in combination,
on the ERP, APD restitution curve, and APD90
Control (n  8) NOD (n  7) LCS  NOD (n  8) HCS (n  7) HCS  NOD (n  8) Washout (n  7)
ERP, ms 2029* 17812 18517 19818* 19022 20210*
APD restitution slope 1.30.1 2.10.2† 1.90.2† 1.60.3 1.90.4† 1.20.1
DI with slope  1, ms 4815 7310† 7013 6614 6510 4411
APD90, ms
PCL  400 ms 2437 2255 22811 24110 22710† 24511
PCL  240 ms 1718 14712 1597 1868 17910‡ 1746
Values are means SE; n number of RVs. ERP, effective refractory period [during regular pacing at cycle length (PCL) 300 ms]; APD,
action potential duration; DI, diastolic interval; APD90, APD at 90% repolarization. *P 0.05 compared with NOD, †P 0.05 compared with
control and washout; ‡P  0.05 compared with control, NOD, and LCS  NOD.
Fig. 2. Endocardial APs recorded with metal microelectrodes during
perfusion with nitric oxide donor (NOD; 50 M sodium nitroprus-
side) in combination with 0.2 g/ml [low concentration sildenafil
(LCS)  NOD] and 2 g/ml [high concentration sildenafil (HCS) 
NOD] sildenafil. A: the first 4 of 12 paced beats were paced at a CL
of 120 ms, whereas the subsequent 8 beats were paced at a CL of 110
ms. Stimulus artifacts (stim) are above each recording. Note increas-
ing AP duration (APD) and AP amplitude alternans with HCS 
NOD that precede ventricular fibrillation. B: plot of the APD gradi-
ents on a beat-to-beat basis during pacing at 110 ms as shown in A.
APD gradients between consecutive beats reach 42 ms with HCS 
NOD, whereas it remains below 10 ms with the other drug regimens.
(Note that the possible emergence of ectopic activity during pacing as
a cause of increased APD gradient cannot be ruled out.)
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might also give the appearance of a focal activity (27).
A recent in vitro study on isolated cardiac myocyte
showed that 30 M sildenafil directly blocked the rapid
outward K current and cause a modest APD prolon-
gation. Sildenafil’s reversal of the NO donors’ shorten-
ing of the ERP seen in the present study is consistent
with the APD prolonging effect of sildenafil reported in
isolated myocytes (8).
Reentrant mechanisms. Another potential mecha-
nism for the high concentration sildenafil-NO donor
combination to promote VT/VF may result from the
ability of this combination to increase both the maxi-
mum slope of the APD restitution and the APD simul-
taneously during rapid pacing. No other drug or drug
combination could manifest these two effects simulta-
neously. With increasing the pacing rate near the rate
at which VT/VF could be induced, the amplitude of the
APD gradient consecutive beats became progressively
amplified, a property that is known to increase wave-
front instability and promote wavebreak, leading to
reentry (7, 25). The pro-VT/VF of the sildenafil-NO
donor combination appears to be also compatible with
the restitution hypothesis of wavefront stability. The
sildenafil-NO donor combination may then trigger VT
by an automatic or a reentrant mechanism and VF by
wavebreak by a mechanism compatible with the resti-
tution hypothesis. More work is needed to clarify this
issue.
Limitations of the Study
It could be argued that our RV preparations may
become unstable as a result of repeat fibrillation/defi-
brillation trials. However, the full reversibility of the
proarrhythmic effects of the sildenafil-NO donor com-
bination upon drug-free washout argues against this
potential pitfall. Another limitation of our study could
be that the effect of the sildenafil-NO donor combina-
tion was evaluated on normal and well-perfused ven-
tricular myocardium. We do not know whether a sim-
ilar response pattern also occurs in diseased and
ischemic ventricular tissue. Finally, it must be empha-
sized that, in the present study, we did not use an
aggressive pacing protocol (burst pacing and high cur-
rents of stimulation) to induce VF (12). The low yield of
VF at baseline therefore could have resulted from the
lack of an aggressive stimulation protocol rather than
from the characteristics of the isolated RVs.
Clinical Implications
Sildenafil is contraindicated in patients with heart
disease that necessitates the concomitant use of ni-
trates (NO donors). Our findings indicate that such a
drug combination might increase ventricular vulnera-
bility to VT/VF. Further studies using models of acute
ischemia and chronic infarction will be needed to de-
termine whether sildenafil alone is also arrhythmo-
genic because many sudden deaths in humans occur in
the absence of nitrates (2).
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